杭州天目山药业股份有限公司股东会议事规则 杭州天目山药业股份有限公司 股东会议事规则 （2025 年 8 月修订） 尚需提交 2025 年第三次临时股东大会审议 杭州天目山药业股份有限公司…………………………………………………………第 1 页 公司董事会应当切实履行职责，认真、按时组织股东会。公司全 体董事应当勤勉尽责，确保股东会正常召开和依法行使职权。 第四条 股东会应当在《公司法》和《公司章程》规定的范围内 行使职权。 第二章 股东会的一般规定 第五条 公司股东会由全体股东组成。股东会是公司的权力机构， 依法行使下列职权： 杭州天目山药业股份有限公司…………………………………………………………第 1 页 （一）选举和更换董事，决定有关董事的报酬事项； 杭州天目山药业股份有限公司股东会议事规则 杭州天目山药业股份有限公司股东会议事规则 第一章 总则 第一条 为规范杭州天目山药业股份有限公司（以下简称"公司"） 行为，保证股东会依法行使职权，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）、《上市公司股东会规则》（以下简称《股东会规则》）、 《上市 ...

天目药业公告，2025年上半年营业收入1.04亿元，同比增长73.97%。净利润1024.78万元，上年同期亏 损1850.07万元。 ...

证券之星消息，8月25日中药板块较上一交易日上涨0.47%，天目药业领涨。当日上证指数报收于 3883.56，上涨1.51%。深证成指报收于12441.07，上涨2.26%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600671 | 天目药业 | 19.80 | 10.00% | 14.40万 | | 2.71亿 | | 000989 | 九芝堂 | 12.71 | 8.08% | 89.51万 | | 11.02亿 | | 300158 | 振东制药 | 66'8" | 7.28% | 133.95万 | | 11.86 乙 | | 301331 | 恩威医药 | 39.08 | 6.95% | 4.06万 | | 1.55亿 | | 002873 | 新大药业 | 13.31 | 6.06% | 53.72万 | | 7.17亿 | | 600594 | 益佰制药 | 4.67 | 4.47% | 88.36万 | | 4.15亿 | | 60 ...

截至13时3分，天目药业涨幅为10.00%，4个交易日内录得2个涨停。最新价19.80元，总市值24.11亿 元，封板资金1.80亿元，成交额2.57亿元，换手率11.23%。 根据分析，可能的影响因素如下： 1. 中报业绩预增显著，预计2025年半年度净利润同比增长145.94%至156.75%，主要由于药品、保健品 及医疗器械等板块布局强化带动产品销量及销售收入增长。 2. 子公司14种药品获再注册批准，涉及补肾强身片等产品，对公司后续生产销售具有积极影响。 来源:金融界 4. 与青岛华东葡萄酿酒共同创新中医药配方在酒水衍生品的生产研发。 5. 设立温泉养老养生大健康产业园，推出休闲养生养老服务。 天目药业主要涉及中药制药、保健品、医疗器械、国企改革、大健康等概念板块。 注：本内容由算法自动生成，不构成投资建议。 3. 公司实际控制人为青岛市崂山区财政局，国企改革预期引发市场关注。 ...

Group 1 - As of August 21, 2025, Tianmu Pharmaceutical's stock price closed at 17.50 yuan, down 1.08 yuan from the previous trading day, with an opening price of 19.06 yuan and a trading range of 16.58% [1] - The company specializes in the research, production, and sales of traditional Chinese medicine, chemical drug formulations, and biological products, covering treatment areas such as cardiovascular, anti-tumor, and anti-infection [1] - On August 21, the stock experienced rapid fluctuations, with a rebound of over 2% within 5 minutes at 9:39 AM, and a decline of over 2% within 5 minutes at 9:35 AM [1] Group 2 - On August 21, the net outflow of main funds was 50.73 million yuan, accounting for 2.38% of the circulating market value, with a cumulative net outflow of 23.92 million yuan over the past five trading days, representing 1.12% of the circulating market value [1]

Group 1 - Tianmu Pharmaceutical (600671) experienced a decline of 5.81% today, with a turnover rate of 17.79% and a trading volume of 409 million yuan, showing a fluctuation of 17.74% [2] - The stock was listed on the Shanghai Stock Exchange due to its daily fluctuation value reaching 17.74%, with a total net sell of 55.03 million yuan from brokerage seats [2] - The top five brokerage seats accounted for a total transaction of 131 million yuan, with a buying amount of 37.90 million yuan and a selling amount of 92.93 million yuan, resulting in a net sell of 55.03 million yuan [2] Group 2 - The main buying brokerage was Goldman Sachs (China) Securities, with a purchase amount of 10.49 million yuan, while the largest selling brokerage was Guotou Securities, with a selling amount of 30.50 million yuan [2] - The stock saw a net outflow of 39.47 million yuan in main funds today, including a net outflow of 7.07 million yuan from large orders and 32.39 million yuan from major funds, with a total net outflow of 20.80 million yuan over the past five days [2] - On April 28, the company reported a first-quarter revenue of 52.29 million yuan, representing a year-on-year growth of 88.55%, and a net profit of 5.09 million yuan, reflecting a year-on-year increase of 152.40% [2] Group 3 - On July 15, the company released a half-year performance forecast, expecting a net profit between 8.50 million yuan and 10.50 million yuan, with a year-on-year change range of 145.94% to 156.75% [3] - The trading data on August 21 showed that the top buying brokerages included Goldman Sachs (China) Securities and others, with significant buying amounts [3][4] - The selling brokerages included Guotou Securities and others, with notable selling amounts, indicating active trading behavior [4]

Company Overview - Tianmu Pharmaceutical's latest stock price is 15.91 yuan, an increase of 0.50 yuan from the previous trading day [1] - The stock reached a high of 16.18 yuan and a low of 15.35 yuan during the day, with a volatility of 5.39% [1] - The trading volume for the day was 76,644 hands, with a transaction amount of 120 million yuan [1] Business Operations - Tianmu Pharmaceutical is primarily engaged in the research, development, production, and sales of traditional Chinese medicine, chemical drug formulations, and biological products [1] - The company's product range covers multiple therapeutic areas, including cardiovascular, anti-tumor, and anti-infection treatments [1] Market Activity - On August 15, Tianmu Pharmaceutical experienced a rapid decline in the morning session, with a drop of over 2% within five minutes, followed by a gradual recovery [1] - The net outflow of main funds for the day was 4.4846 million yuan, while the cumulative net inflow of main funds over the past five trading days was 13.0701 million yuan [1]

Core Viewpoint - Tianmu Pharmaceutical has made significant progress in product registration and market adaptation, focusing on innovative health products while addressing investor concerns about its growth strategy and market positioning [2][3][4]. Group 1: Financial Performance - As of August 8, 2025, Tianmu Pharmaceutical's stock closed at 14.91 yuan, up 2.12%, with a trading volume of 66,600 shares and a transaction value of 98.26 million yuan [1]. - The company reported a significant improvement in its financial performance, with a net profit margin exceeding 22% in 2024, and the stock price increased by over 50% from the end of 2024 to June 2025 [4]. Group 2: Product Development and Market Strategy - The company has received production licenses for approximately 40 new drugs, with six products currently in production and sales, including sugar-free formulations to cater to market demands [2][3]. - Tianmu Pharmaceutical is actively conducting market research to prioritize the production of drugs with high market demand and favorable prospects, aiming to enhance product diversity and applicability [3]. - The company is also exploring collaborations with well-known manufacturers to innovate health products that combine traditional Chinese medicine with consumer goods [3]. Group 3: Investor Relations and Corporate Governance - The company has maintained an open but cautious approach towards mergers and acquisitions, monitoring market trends and potential integration opportunities [4]. - As of July 31, 2025, the number of shareholders stood at 10,088, indicating a stable investor base [5]. - On August 8, 2025, the net inflow of main funds was 3.85% of the total transaction value, reflecting investor interest in the company's stock [5].

Market Performance - The two markets opened lower on Friday, with the Shanghai Composite Index closing at 3559.95 points, down 0.37%, and the Shenzhen Component down 0.17% [1] - The total trading volume was 15,984 billion, a significant decrease of 3,377 billion (-17.44%) compared to Thursday [1] - Over 80% of industry sectors saw gains, with warehousing logistics, construction decoration, software, paper printing, and ecological environment sectors leading the rise [1] Industry Highlights - The Chinese medicine sector experienced a significant surge, with Weikang Pharmaceutical hitting the 20% daily limit, alongside other companies like Tianmu Pharmaceutical and Guizhou Bailin also reaching the limit [1] - The photovoltaic sector also performed well, with Jiejia Weichuang and Shuangliang Energy both hitting the daily limit [1] Technical Analysis - The three major indices showed a volume contraction and closed with long upper shadows, indicating a potential reversal after five consecutive weeks of gains [2] - The Shanghai Composite, Shenzhen Component, and ChiNext Index fell by 0.94%, 1.58%, and 0.74% respectively for the week, with total trading volume at 8.93 trillion, down 1.76% from the previous week [2] Investment Strategy - Companies are advised to reduce positions in high-flying stocks that have seen significant gains, while looking to invest in undervalued small and mid-cap growth stocks that have shown strong performance in Q1 and exceeded expectations in H1 [2] - There is a recommendation to allocate some resources towards brokerage stocks in anticipation of the upcoming half-year and third-quarter earnings reports [2]

Core Viewpoint - The traditional Chinese medicine (TCM) sector is experiencing significant opportunities due to favorable policies and market developments, with a notable surge in stock performance among TCM companies [6][9]. Market Performance - On August 1, the A-share market saw a slight decline, with the Shanghai Composite Index down 0.37%, Shenzhen Component Index down 0.17%, and ChiNext Index down 0.24%. However, over 3,300 stocks rose in the market [1][2]. - The TCM sector led the market with a substantial increase, as evidenced by the 1.78% rise in the Shenwan TCM Index, with several companies, including Weikang Pharmaceutical and Tianmu Pharmaceutical, hitting the daily limit [5][6]. Policy and Industry Developments - The establishment of the Yangtze River Delta TCM Concept Verification and Achievement Transformation Center in Shanghai aims to enhance the commercialization of TCM research and development [6]. - The State Council's 2025 directive emphasizes the protection and utilization of TCM resources, indicating a supportive regulatory environment for the industry [6]. Company Performance - Notable TCM companies reported significant profit growth in the first half of 2025. For instance, Darentang's net profit is expected to reach between 18.4 billion to 20 billion yuan, marking a year-on-year increase of 180% to 204% [9][11]. - Jilin Aodong anticipates a net profit of approximately 12.36 billion to 12.9 billion yuan, reflecting a year-on-year growth of 130% to 140% [9][11]. - Tianmu Pharmaceutical successfully turned a profit during the reporting period, driven by enhanced sales in pharmaceuticals and medical devices [10]. Investment Insights - Analysts suggest that the TCM sector is poised for growth, driven by innovative products and strong brand recognition, particularly in high-value markets [7][8]. - The focus on stable cash flow to support R&D expenditures is expected to be a key strategy for TCM companies moving forward [7].